Market Research Reports Breast Cancer Patient Digital Landscape | Page 2

The Global Breast Cancer Market is segmented into Type, Treatment, End-User and Region. Based on
the Type, the Global Breast Cancer Market is classified into invasive ductal carcinoma, invasive
lobular carcinoma and others. On the basis of Treatment, Global Breast Cancer Market is sub-
segmented into chemotherapy, surgery & radiation therapy, targeted therapy, biologic therapy,
hormone therapy and other. Based on the End-User, the Global Breast Cancer Market is divided into
hospital pharmacies, private pharmacies and others.
In terms of the geographic analysis, North America accounts the largest Breast Cancer Market
followed by Europe. United States, followed by Canada, is the largest market for Breast Cancer in
North America. Major driving factor for this market is increasing prevalence of breast cancer in the
region. Germany, France and the U.K. are some of the largest markets for breast cancer in Europe
region. However, APAC represents the fastest growing region in the Breast Cancer Market. This is
due to improving healthcare infrastructure and increasing awareness among people about breast
cancer.
Latest Business News:
Eli Lilly and Company (June 04, 2019) – U.S. FDA Accepts New Drug Application for Triple
Combination Tablet for Adults with Type 2 Diabetes – The U.S. Food and Drug Administration (FDA)
has accepted the New Drug Application (NDA) for the investigational fixed-dose combination tablet
of empagliflozin, linagliptin and metformin extended release (XR) for the treatment of adults with
type 2 diabetes, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced.
"Millions of adults with type 2 diabetes take multiple medicines to control their condition," said
Mohamed Eid, M.D., M.P.H., M.H.A., vice president, Clinical Development & Medical Affairs,
Boehringer Ingelheim Pharmaceuticals, Inc. "If approved by the FDA, the combination tablet would
be one of the first single-pill options with three complementary mechanisms of action to help
manage blood glucose in adults with type 2 diabetes who could benefit from having empagliflozin
and linagliptin as part of their treatment regimen, in addition to metformin."
Top Leading Key Manufacturers are: Pfizer, Novartis AG, Apthera Inc, Astellas, Bipar Sciences, Sanofi
S.A., Eli Lilly and Company, AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, Teva
Pharmaceutical Industries, Sun Pharmaceutical Industries Ltd, Accord Healthcare, Bristol-Myers
Squibb Company, Hospira, Inc., Bayer AG and others. New product launches and continuous
technological innovations are the key strategies adopted by the major players.
Region segment: This report is segmented into several key regions, with sales, revenue, market
share (%) and growth Rate (%) of Breast Cancer in these regions, from 2013 to 2023 (forecast),
covering: North America, Europe, Asia Pacific, Middle East & Africa and South America
Purchase this report online with 50 Pages, List of Tables & Figures and in-depth Table of Contents
on “Global Breast Cancer Market Report 2019” @ https://www.businessindustryreports.com/buy-
now/162994/single .
About us
BusinessindustryReports.com is digital database of comprehensive market reports for global
industries. As a market research company, we take pride in equipping our clients with insights and